Cyron Therapeutics has signed a joint research agreement with the prestigious Harvard Medical School for brain disease treatment development. The agreement focuses on developing treatments for neurodegenerative diseases including Alzheimer's and Parkinson's.
The two institutions will conduct joint research worth $20 million over the next 5 years, combining Harvard Medical School's basic research capabilities with Cyron's drug development technology. They particularly plan to utilize Harvard's extensive patient data and biomarker research results.
The agreement includes a researcher exchange program, providing Cyron Therapeutics researchers opportunities to train at Harvard. Intellectual property from joint research will be co-owned, with Cyron having preferential commercialization rights.
Dr. Michael Greenberg, Chair of Neuroscience at Harvard Medical School, expressed optimism about the collaboration, stating, "Cyron's innovative drug delivery technology has great potential in overcoming the blood-brain barrier."